Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
about
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trialsA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaNew investigational drugs with single-agent activity in multiple myelomaThe next generation of novel therapies for the management of relapsed multiple myeloma.Platelet activation determines the severity of thrombocytopenia in dengue infection.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Multiple myeloma in the marrow: pathogenesis and treatments.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Carfilzomib boosted combination therapy for relapsed multiple myelomaBlockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.A practical review on carfilzomib in multiple myeloma.Practical Approaches to the Management of Dual Refractory Multiple Myeloma.The safety of pomalidomide for the treatment of multiple myeloma.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Sorafenib for the treatment of multiple myeloma.How is patient care for multiple myeloma advancing?Pomalidomide in the management of relapsed multiple myeloma.Management of high-risk Myeloma: an evidence-based review of treatment strategies.Current Review on High-Risk Multiple Myeloma.Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.Treatment of Relapsed/Refractory Multiple Myeloma.Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.Developments in the Field of Myeloma in the Last Decade.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.Emerging drugs and combinations to treat multiple myeloma.Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.Therapy sequencing strategies in multiple myeloma: who, what and why?Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.Integration of Novel Agents into the Care of Patients with Multiple Myeloma.Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
P2860
Q26741620-4E904836-BD4F-4C88-8571-94DD4E6D6CDAQ28067148-C45A0202-C599-4303-80CC-F3DB0986E458Q28071551-FEC911A4-2DB2-4194-B10B-EB155400E6F4Q30248534-614D96A6-0D86-4706-AFFA-E575FFF1C8F1Q30836939-26F73F49-D2AD-491D-8218-529B991C444FQ33437691-FD55E320-9271-44D4-9DA0-89499872AFFBQ33439437-10DF01F8-F524-4FF2-A11B-AFD8FD983A49Q33442923-025B97C8-1C00-4AA1-935C-0BF9C2979DFEQ33443411-AF4CEF1F-2D85-49B1-864F-F269ABE380A7Q36725401-9363DC70-9651-43FC-A7E3-AA7EEAB3CF09Q37037265-C11EA601-0EBB-4768-98D5-7D1D74FB1E82Q37652953-B105AE42-78BD-4F30-B93A-E3BF7BD00CAFQ37705854-CF2241BC-E09E-4EA6-B65B-73C93586D9BDQ38672091-9B976095-EA37-4582-B21E-A3B1ED9173A7Q38740271-3D2A1DD8-C735-4F8B-99E4-5AF9E801EB96Q38742700-EDDF019D-1034-4976-8FAB-41CCC73ABF02Q38749362-EC3D0038-EF49-4BB3-8C11-3F531DA6AB5CQ38757067-BA862821-D3B9-429B-96BF-1078D81FAADFQ38783055-32E9B2D6-1ED5-4A5F-A13D-A327BE891A70Q38786149-053225BF-D8E0-421C-9A06-791027B928CBQ38855510-7BBE35E8-5D50-4ED1-80AA-FE06B6400DEEQ38874675-67EFE4B4-4EB5-470D-94EA-3111637B12EBQ38895167-E5A4DBE0-5666-4932-8C61-7191DB78A23AQ38896473-11E65DFE-5386-4343-9D97-CA4149F35AC6Q38970597-22AB4E29-3B12-4E5A-A5AF-A2D59F0A64AFQ39022303-A636E31E-E1D1-4D60-8056-66C4D39201FCQ39117277-2454C8B3-BCAD-44FF-B85D-C47923EEEF19Q39134193-48C4981E-7A6C-41BF-AAB7-B968A9F5BDCBQ39138108-FB94DDB5-2B8B-45BD-BA59-BCB31F03E27AQ39177792-3FABAA11-085F-40B3-9E33-1FFB8EBE3340Q39234159-C9766EAF-4509-48EE-9A40-D6AAE82A58AEQ40163287-6C0DD4CD-3773-4908-A305-C23277B6247FQ41694198-FFB80F97-3035-43B2-8B3C-779BF9FB0DD1Q42425704-964549A5-AC7F-4305-AC6F-A27804A560C6Q44597478-568D6F71-72D5-4C8A-ADD6-76DEC6B4DD77Q45946305-9316987D-C01A-4E0A-9488-57F9AC965596Q46147631-E367BE62-795E-47FB-87D0-97EE84358F8AQ46754093-ABC05274-ED31-405F-B5A3-320807EDD21DQ47236245-4733BEE8-5B65-418E-B78F-8885CBA17AF5Q47283493-7BA0E6EF-C94E-4A3D-ABE7-6474CD34625A
P2860
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
@ast
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
@en
type
label
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
@ast
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
@en
prefLabel
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
@ast
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
@en
P2093
P2860
P50
P1433
P1476
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
@en
P2093
Brian G M Durie
Christina L Gomes
Cristina Gasparetto
Dan T Vogl
Edward A Stadtmauer
Jatin J Shah
Jonathan L Kaufman
Natalia Pascucci
Rafat Abonour
Suzanne Lentzsch
P2860
P304
P356
10.1182/BLOOD-2015-05-643320
P407
P577
2015-09-17T00:00:00Z